Business Maverick

Business Maverick

China Vaccine Stocks Rebound as Merkel Opposes Patent Waiver

Vials of the Pfizer Inc.-BioNTech SE Covid-19 vaccine in a box at the Lux Med oncology hospital in Warsaw, Poland, on Thursday, Feb. 25, 2021. The country of 38 million has so far administered 2,990,683 vaccine doses, including 1,031,518 with second dose. Photographer: Lukasz Sokol/Bloomberg

Shares of Covid-19 vaccine developers in Asia got some relief after the German Chancellor rejected a U.S. proposal to waive patent protections for coronavirus shots.

Chinese vaccine makers rebounded after slumping on Thursday following the initial news that the U.S. would support discussions for a waiver of the rights to develop vaccines. The Biden administration’s plan would create “severe complications” for the production of vaccines, a German government spokeswoman said Thursday in an email.

Shanghai Fosun Pharmaceutical Group Co., which has the rights to develop and market BioNTech SE’s shot in China, advanced as much as 7% in Hong Kong after sinking 14% the previous day. Walvax Biotechnology Co. gained 3.7% in Shanghai, one of the best performers in the benchmark CSI 300 Index.

In the U.S., Pfizer Inc., BioNTech SE, Novavax Inc. and CureVac NV all pared an earlier slump.

Some analysts had urged for caution to the news prior to Merkel’s announcement. The Biden administration’s plans will only open up a negotiation at the WTO and other countries and members remain unwilling, said Barclays analyst Carter Gould in a note.

For Evercore ISI analyst Umer Raffat, U.S. support didn’t mean it was a “100% done deal” as other countries are also opposed. It “remains to be seen if U.S. leadership’s position sways others,” Raffat wrote in a note.

With many countries struggling with a resurgence of the virus, U.S. Trade Representative Katherine Tai said Wednesday the Biden administration will take part in negotiations for the text of a waiver of the rights at the World Trade Organization. The European Union said Thursday it was willing to participate.

Chinese drugmakers plunge as U.S. backs vaccine IP waiver

Big Business

Vaccines have been a big business for the firms that make them, with Pfizer, BioNTech’s partner outside of China, raising its forecast for 2021 vaccine sales to $26 billion just this week.

Read more: Analysts say investor fears of U.S. vaccine waiver support are overblown

The International Federation of Pharmaceutical Manufacturers & Associations condemned the move as “disappointing.”

“A waiver is the simple but the wrong answer to what is a complex problem,” the group said in a statement. “Waiving patents of Covid-19 vaccines will not increase production nor provide practical solutions needed to battle this global health crisis.”


Comments - Please in order to comment.

Please peer review 3 community comments before your comment can be posted


This article is free to read.

Sign up for free or sign in to continue reading.

Unlike our competitors, we don’t force you to pay to read the news but we do need your email address to make your experience better.

Nearly there! Create a password to finish signing up with us:

Please enter your password or get a sign in link if you’ve forgotten

Open Sesame! Thanks for signing up.

Daily Maverick Elections Toolbox

Download the Daily Maverick Elections Toolbox.

+ Your election day questions answered
+ What's different this election
+ Test yourself! Take the quiz